



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

11 May 2021

ANNOUNCEMENT



Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.


OPERATIONAL UPDATE

The directors (the “**Directors**” or the “**Board**”) of Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) wish to inform the shareholders of the Company and potential investors of the following update in respect of its operations.

Venturex Resources Limited

We are pleased to inform shareholders and potential investors that the marked-to-market performance in respect of the Company’s investment in Venturex Resources Limited (“**VXR**”, ASX: VXR) has continued its significant improvement from our last operations update of 2 March 2021 where the Group has increased its unrealised gain to US\$10.74 million (or approximately HK\$83.77 million) and a marked-to-market value of US\$13.13 million (or approximately HK\$102.41 million) on its VXR shareholding as at 10 May 2021, representing a 450% increase from 31 December 2020.

For the benefit of shareholders, VXR gave notice of a general meeting of shareholders convened to be held on 9 June 2021 to consider an extensive recapitalisation plan that was announced by the company on 24 February 2021. The recapitalisation plan is designed to re-set the company for growth as a supplier of new-generation energy and technology materials and to advance the funding and development of its 100% owned flagship Sulphur Springs copper-zinc project in



Western Australia's Pilbara region. The Sulphur Springs project hosts a total mineral resource comprising 17.4 million tonnes grading 1.3% copper, 4.2% zinc and 17g/t silver (refer ASX announcement, 21 March 2018). VXR completed a definitive deasibility study (refer ASX announcement, 10 October 2018) on the Sulphur Springs project which demonstrated an economically robust project. Since then, metal prices (particularly copper) have increased substantially, reaching an all time high last week. Sulphur Springs is reported by VXR to have a + 10 years mine life that can produce 15,000 tonnes copper concentrate and 35,000 tonnes zinc concentrate per annum, which at today's metal prices will generate significant income.

The recapitalisation announced in February 2021 will see an accomplished new board and management team led by Bill Beament, with a strong track record of success in the international mining industry, join VXR.

If approved by VXR's shareholders, the funding package under the recapitalisation introduces:

- (a) funding of A\$18.80 million at A\$0.08 per share by way of a A\$14 million placement to sophisticated investors, of which Mr Beament will contribute A\$8.90 million, and a fully underwritten one-for-seven entitlement offer to existing shareholders; and
- (b) an option structure to source additional funding of A\$39.60 million, increasing the total value of the strategic funding package to A\$58 million, putting VXR in a strong position to fast-track the development of Sulphur Springs.

VXR's shareholders will have the opportunity to participate in this funding package via the fully underwritten one-for-seven entitlement offer, through which they will also receive one free attaching option for every two shares subscribed for, exercisable at A\$0.135 within 24 months. The entitlement offer will be available to all shareholders on the VXR's share register on the record date, which is Wednesday, 16 June 2021, on the same terms and price as the placements. It is the Company's current intention to participate in the entitlements offering.

Plethora Solutions Holdings plc ("Plethora")

The People's Republic of China ("China" or the "PRC")

The Company has been provided with an update from Wanbang Pharmaceutical Group Co., Ltd. ("**Wanbang Pharmaceutical**") of its clinical study for seeking approval of an import licence for Senstend™ (the marketing name of Fortacin™ in China) from the National Medical Products Administration ("**NMPA**") of the PRC:

Start date:	Q4 2021 (subject to approval from NMPA), moved from April/May 2021
Study type:	Clinical trial, multi-center, randomised, double-blinded placebo controlled study
Estimated enrolment:	285 subjects increased from 150
Primary endpoint:	To determine the effects of Senstend™ on the Index of Premature Ejaculation (IPE) and the Intra-vaginal Ejaculation Latency Time (IELT)
Secondary endpoint:	To evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners
Estimated study completion date:	October 2022, being 12 months from the study start date

The Group has been informed by Wanbang Pharmaceutical that while it has ordered clinical supplies (both active and placebo) from Pharmaserve (North West) Limited (“**PSNW**”), the manufacturer of Senstend™ (China)/Fortacin™ (rest of the world), with the aim of supplies being ready for the commencement of the clinical trial, two ingredients (being PEG/Povidone) for the placebo will not be in stock until July 2021, at the earliest. The main reason for this delay in the supply is that the COVID-19 pandemic has disrupted PSNW’s supply chain and some of its key materials for manufacturing the placebo and active.

In respect of the commercial scale up to increase the current batch size per each manufacturing run to 50,000 units from 15,000 units, the development work will commence in June 2021 after the latest commercial batch has been manufactured in May 2021. This is designed, if successful, to meet Wanbang Pharmaceutical’s requirements for China and the over-the-counter’s requirements of Recordati S.p.A. in the European Union and the United Kingdom (“**UK**”).

If the clinical study meets its endpoints and the NMPA has granted an import licence for Senstend™, then US\$5 million (or approximately HK\$39 million before deduction of PRC withholding tax) will be payable to the Group from Wanbang Pharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US\$2 million (or approximately HK\$15.60 million before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Pharmaceutical.

United States Approval and Commercialisation Progress

Further to our update of 11 January 2021 on the key findings from a leading global marketing consulting firm, Medical Marketing Economics (“**MME**”) that the Group engaged to assess the United States (“**US**”) payer’s willingness to cover Fortacin™ and the level of price sensitivity for coverage, the Group is able to report on the final findings from MME.

The Company is pleased to announce that MME has recently completed a comprehensive analysis of patients, physicians and healthcare providers across the US. The survey has confirmed that a price of US\$90 to US\$150 is sustainable for the proposed US presentation of Fortacin™. Further, the target product profile would result in over 80% being prepared to consider Fortacin™ as an effective treatment, an outstanding result. MME has historically undertaken equivalent assessments for most major pharmaceutical companies.

A key determinant of the commercial opportunity in the US is the price that the patient or health care provider is prepared to pay. This is analysed by the presentation of the target product profile to physicians, healthcare providers and patients, set against various pricing options. The resultant model of “price point sensitivity” is used for setting the market price or, in the case of Plethora, will be used as a basis for the ongoing licensing discussions with potential US partners.

In respect of the US Phase II validation study, the clinical research organisation has “locked” the data base with top line results expected in June 2021. The Group remains on target to submit the study to the US Food and Drug Administration (“**FDA**”) at the end of June 2021 depending on the results of the study. On the assumption that the trial is sufficient to convince the FDA that the Premature Ejaculation Bothersome Evaluation Questionnaire serves as an appropriate measure for support of a label claim, the pivotal Phase III study could commence in the latter half of 2021, with New Drug Application submission possible in late 2022, giving a Prescription Drug User Fee Act date at the end of 2023.

Despite the difficulties presented by the COVID-19 pandemic, particularly as it relates to securing face-to-face meetings, the Group’s strategy remains to continue negotiations with potential commercial strategic partners for the US market, while we complete the submission of the study to the FDA, with the aim of securing a partner just ahead of or while we conduct the Phase III trial.

The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

Jamie Gibson, Chief Executive Officer of the Company, said, “This extensive recapitalisation plan will help to fast track the development of Sulphur Springs into a producing copper and zinc mine and enhance the competitiveness, operations and the development of the Company’s business in the new-generation energy industry under the leadership of Mr Beament, a veteran in the resource sector. It also enables VXR’s shareholders and its financial stakeholders to benefit from the strategy and will be offered the chance to acquire further shares and options in VXR on the same terms to tape into the high-growth industry.

Together with the promising commercialisation progress of Fortacin™ in the US, Taiwan, Hong Kong and Macau, the Company is poised to capture significant market share through its premature ejaculation treatment around the world in the coming years.”

Taiwanese and Macau Commercialisation Progress

We are pleased to report that Orient EuroPharma Co., Ltd. (“**OEP**”), the Group’s commercial strategic partner for Taiwan, Hong Kong Special Administrative Region (“**Hong Kong**”), Macau Special Administrative Region (“**Macau**”) and other select countries in Asia, has launched Fortacin™, the Group’s prescription treatment for premature ejaculation, for sale in Macau from 1 March 2021, following the launch in Hong Kong in January 2021. OEP has also informed the Group that it now expects to launch Fortacin™ in Taiwan (its home market) in Q2 2021 due to PSNW not being able to deliver the product until June 2021, at the earliest. The Group will generate a low teens royalty of OEP’s net sales of Fortacin™ in these markets.

Deep Longevity, Inc

On 14 December 2020, the Company completed the acquisition of Deep Longevity, Inc (“**Deep Longevity**”). Deep Longevity is a company focusing on the development and commercialisation of artificial intelligence-based biomarkers of human aging commonly referred to as the ‘deep aging’ clocks. In July 2020, Deep Longevity announced the completion of a funding round led by ETP Ventures and the Human Longevity and Performance Impact Venture Fund, with participation from BOLD Capital Partners, Longevity Vision Fund, Oculus co-founder and former chief software architect Michael Antonov through Formic Ventures and LongeVC.

The company operates in three segments:

1. Direct to Consumer through its Young.AI app providing biological, behavioural, and psychological aging clock tracking and recommendations designed to slow down or reverse biological aging. The company is also constantly developing and patenting new aging clocks utilising new data types.

2. The provision of its AgeMetric™ biological age reports to clinics and medical doctors for a fee.
3. It provides age prediction and recommendation services via software as a service (SaaS) API and on-premises instalment to the life and health insurance companies.

The company is also engaged in longevity education for physicians.

Since July 2020, Deep Longevity has achieved multiple research and commercial milestones. For example, in September 2020, Deep Longevity released the first beta-version of its Young.AI mobile app via the Apple App Store and initiated a pilot study with a limited number of (Polina-stats) users. Since then, the company has conducted a number of pilot tests to understand the user needs and behaviours releasing 8 versions of the Young.ai app (currently in version 1.08) and is preparing to launch and market the production version with an integrated payment system.

Deep Longevity has partnered with clinics in the US and UK including Human Longevity, Inc, Boulder Longevity Institute, Peak 1 Wellness, Healthy Hire Healthy Retire, Wellness Corner, My Care Express, Hooke London, and Epigenetic House. Deep Longevity has also initiated pilot studies with leading longevity clinics in Hong Kong and China that are currently ongoing.

The company has developed the Introduction to Longevity Medicine for Physicians course and launched it on Udemy.com platform with over 2600 learners registered and is preparing to launch the course on its own Longevity.Degree platform in both English and Chinese. The English version of the course received the Continuing Medical Education (CME) approval from the Medical Society of Delaware (MSD).

Deep Longevity is actively engaged with a number of leading life insurance companies and is exploring pilot engagements in both underwriting, customer acquisition and engagement.

On the research front, Deep Longevity has published and applied for patents on a number of new aging clocks. Its DeepMAge, deep methylation aging clock is likely to be the most accurate methylation aging clock on record. The company also published and applied for patent for MindAge, its psychological aging clock, a predictor of human psychological age based on survey data. This clock is now being integrated into the company's mental health strategy and wellbeing offering. The company test-piloted the clock in January and as of 18 April 292,261 people have completed the survey (without any marketing spending on the company's part) demonstrating that there is significant demand for this offering.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Executive Director

Directors of the Company:

James Mellon (*Chairman*)*
Jamie Gibson (*Chief Executive Officer*)
David Comba#
Julie Oates#
Mark Searle#
Jayne Sutcliffe*

* *Non-Executive Directors*

Independent Non-Executive Directors

Hong Kong, 11 May 2021